cs1 car-t cell
Cell therapyexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04541368)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SLAM family member 7Immunity, passive
SLAMF7 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04541368 | Early Phase 1 (Phase 1) | Dec 31, 2020 | Yake Biotechnology Ltd., Zhejiang University |
| NCT06321705 | N/A | — | Abbott, Cereno Scientific AB, Worldwide Clinical Trials |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 1 | 0 | 1 | — |
| Cereno Scientific AB | For profit | 1 | 1 | 1 | — |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | — |
| Yake Biotechnology Ltd. | Government | 1 | 0 | 1 | 2020 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1